The effectiveness and safety of iguratimod, used for rheumatoid arthritis, could be influenced by genetic variations in genes like NAT2, ABCG2, ABCB1, and CYP2C19, which impact drug metabolism, distribution, and elimination, potentially affecting iguratimod's degradation, efficacy, and toxicity.